论文部分内容阅读
目的:对孟鲁司特钠片联合沙美特罗替卡松粉吸入剂对支气管哮喘的临床治疗效果进行探讨与研究。方法:依照随机抽取的方式把2010年5月到2013年5月我院诊治的84例支气管哮喘患者分成治疗和观察组两组,每组各42例。单纯利用布地奈德气雾剂来治疗观察组,联合运用孟鲁司特纳片+沙美特罗替卡松粉吸入剂来治疗治疗组,对两组的ACT(哮喘控制测试)评分和肺功能指标进行对比,并对两组所出现的不良反应情况进行观察。结果:与治疗之前相比,两组的PEF(呼吸流速峰值)、MMEF(最大呼气中期流速)以及FEV1(第一秒用力呼气量)水平都得到了提高(P<0.05),在提高幅度上,治疗组明显比观察组高(P<0.05);与治疗之前相比,两组的ACT评分均得到了提高(P<0.05),治疗组为25.77±1.58,观察组为21.16±1.63,治疗组明显高于观察组(P<0.05)。所有患者均没有出现不良反应。结论:在治疗支气管哮喘上,孟鲁司特钠片联合沙美特罗替卡松粉吸入剂能够对患者肺功能进行明显改善,治疗效果显著,能使激素应用的不良反应得到减轻,值得临床推广。
OBJECTIVE: To investigate and study the clinical effect of Montelukast sodium combined with salmeterol and fluticasone powder inhaler on bronchial asthma. Methods: Eighty-four patients with bronchial asthma diagnosed and treated in our hospital from May 2010 to May 2013 were randomly divided into treatment and observation groups, 42 in each group. Patients in the observation group were treated with budesonide aerosol alone, montelukast and salmeterramine powder inhalers were used to treat the treatment group, ACT (asthma control test) score and lung function Indicators were compared, and two groups of adverse reactions observed. RESULTS: Both PEF (peak flow rate), MMEF (maximum expiratory flow rate), and FEV1 (forced expiratory volume in the first second) levels were increased (P <0.05) in both groups before treatment, The amplitude of ACT was significantly higher in the treatment group than in the observation group (P <0.05). The ACT scores of both groups were significantly higher than those before the treatment (P <0.05), the treatment group was 25.77 ± 1.58 and the observation group was 21.16 ± 1.63 , The treatment group was significantly higher than the observation group (P <0.05). All patients showed no adverse reactions. Conclusion: In the treatment of bronchial asthma, montelukast sodium tablets combined with salmeterol and fluticasone powder inhalation can significantly improve lung function in patients with significant therapeutic effect, which can reduce the adverse effects of hormone application, is worthy of clinical promotion .